Tags

Type your tag names separated by a space and hit enter

Safety of olanzapine.
J Clin Psychiatry. 1997; 58 Suppl 10:13-7.JC

Abstract

Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized. The primary clinical trial safety database included 2500 patients treated with olanzapine, 810 with haloperidol, and 236 with placebo. The overall discontinuation rate from olanzapine treatment was low. Significant adverse events included somnolence, weight gain, and asymptomatic treatment-emergent transaminase elevation. Minimal parkinsonism and akathisia with rare dystonia were noted. No hematotoxicity was noted. The incidence of seizures and sexual dysfunction was rare.

Authors+Show Affiliations

Psychopharmacology Division, Eli Lilly and Company.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis

Language

eng

PubMed ID

9265911

Citation

Beasley, C M., et al. "Safety of Olanzapine." The Journal of Clinical Psychiatry, vol. 58 Suppl 10, 1997, pp. 13-7.
Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58 Suppl 10:13-7.
Beasley, C. M., Tollefson, G. D., & Tran, P. V. (1997). Safety of olanzapine. The Journal of Clinical Psychiatry, 58 Suppl 10, 13-7.
Beasley CM, Tollefson GD, Tran PV. Safety of Olanzapine. J Clin Psychiatry. 1997;58 Suppl 10:13-7. PubMed PMID: 9265911.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety of olanzapine. AU - Beasley,C M,Jr AU - Tollefson,G D, AU - Tran,P V, PY - 1997/1/1/pubmed PY - 2001/3/28/medline PY - 1997/1/1/entrez SP - 13 EP - 7 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 58 Suppl 10 N2 - Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized. The primary clinical trial safety database included 2500 patients treated with olanzapine, 810 with haloperidol, and 236 with placebo. The overall discontinuation rate from olanzapine treatment was low. Significant adverse events included somnolence, weight gain, and asymptomatic treatment-emergent transaminase elevation. Minimal parkinsonism and akathisia with rare dystonia were noted. No hematotoxicity was noted. The incidence of seizures and sexual dysfunction was rare. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/9265911/Safety_of_olanzapine_ L2 - http://www.psychiatrist.com/jcp/article/pages/1997/v58s10/v58s1003.aspx DB - PRIME DP - Unbound Medicine ER -